Beneficio del tratamiento de la fibrilación auricular en pacientes diabéticos
El tratamiento hipotensor mejora especialmente el pronóstico de los pacientes con diabetes tipo 2 y fibrilación auricular.
Leer texto completo: “Beneficio del tratamiento de la fibrilación auricular en pacientes diabéticos”
ArtÃculos de referencia:
El tratamiento glucémico intensificado reduce la microangiopatÃa pero no la morbimortalidad cardiovascular en pacientes con diabetes mellitus tipo 2. Impacto Vol 1 Nº 6
Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microv ascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40.
Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30(9):1128-35.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370.
Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:e149.
Ostgren CJ, Merlo J, Ra°stam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004;6:367–374.
Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation:prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol. 2000;4(2):369-82.
Fuente: Suplemento Excelencia ClÃnica: Impacto. Septiembre 2009;2(8). Actualidad.
